Ardy Arianpour is now senior vice president of business development at Ambry Genetics. He previously served as vice president of business development at the company. Arianpour joined Ambry in 2009 after holding several positions at Cogenics.
Following the US Supreme Court's decision two weeks ago to strike down Myriad Genetics' central patent claims to the BRCA1 and BRCA2 genes, several US genetic testing laboratories have been gearing up to snatch a piece of the BRCA testing market in this country, previously Myriad
This month, Myriad announced that it plans to launch a hereditary cancer panel based on next-generation sequencing by the end of the year and that it would phase out its Sanger-based BRACAnalysis test by 2015, causing some experts to speculate how Myriad's entry into next-gen seq
The American College of Medical Genetics and Genomics last week issued a clarification to recommendations it released in March about how providers of clinical exome and whole-genome sequencing tests should deal with incidental findings.
Ambry Genetics and GE Healthcare, who each released a new 26-gene sequencing service last week, have disclosed that both of their new services are based on Illumina's TruSight Tumor panel for somatic variant detection in solid tumors on the MiSeq platform.
Illumina has launched TruSight Tumor Content, an amplicon-based panel that targets 26 oncogenes and tumor suppressor genes selected associated with common solid tumors, including lung, colon, melanoma, gastric, and ovarian cancer.
PHOENIX (GenomeWeb News) – Whole-exome sequencing is inching its way into the clinic, and at the American College of Medical Genetics and Genomics annual meeting held here geneticists and clinicians showed how such sequencing could be used to find diagnoses for patients whose conditions had remai